These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 8745594

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Treatment of chronic hepatitis C with interferon-alpha. Clinical histological and virological implications.
    Olaso V, Córdoba J, Berenguer M, Prieto M, Lainez B, Argüello L, Valverde J, Pascual S, Gobernado M, Berenguer J.
    Rev Esp Enferm Dig; 1997 Jul; 89(7):531-50. PubMed ID: 9265839
    [Abstract] [Full Text] [Related]

  • 3. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
    Sostegni R, Ghisetti V, Pittaluga F, Marchiaro G, Rocca G, Borghesio E, Rizzetto M, Saracco G.
    Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
    [Abstract] [Full Text] [Related]

  • 4. Parameters predicting response to alpha-interferon treatment in chronic hepatitis C.
    Glück T, Seelig R, Dette S, Bühring HJ, Renz M, Kwon S, Wiedmann KH, Weber P.
    Hepatogastroenterology; 1997 Aug; 44(14):484-91. PubMed ID: 9164523
    [Abstract] [Full Text] [Related]

  • 5. Biochemical and virological response of chronic hepatitis C after treatment with interferon-alpha for 6 or 12 months: predictors of sustained remission.
    Papatheodoridis GV, Katsoulidou A, Touloumi G, Delladetsima JK, Hatzakis A, Tassopoulos NC.
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):469-75. PubMed ID: 8804876
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone.
    Scotto G, Fazio V, Tantimonaco G.
    Ital J Gastroenterol; 1996 Dec; 28(9):505-11. PubMed ID: 9131395
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK, Bansal SB, Gupta A, Gulati S, Kumar A, Prasad N.
    Clin Transplant; 2006 Dec; 20(6):677-83. PubMed ID: 17100715
    [Abstract] [Full Text] [Related]

  • 12. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.
    Zeuzem S, Schmidt JM, Lee JH, von Wagner M, Teuber G, Roth WK.
    Hepatology; 1998 Jul; 28(1):245-52. PubMed ID: 9657119
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Prospective comparison of four lymphoblastoid interferon alpha schedules for chronic hepatitis C. A multivariate analysis of factors predictive of sustained response to treatment.
    Bellobuono A, Mondazzi L, Tempini S, Silini E, Idéo G.
    Eur J Gastroenterol Hepatol; 1997 Dec; 9(12):1169-77. PubMed ID: 9471022
    [Abstract] [Full Text] [Related]

  • 15. Therapy of hepatitis C: patients with cirrhosis.
    Schalm SW, Fattovich G, Brouwer JT.
    Hepatology; 1997 Sep; 26(3 Suppl 1):128S-132S. PubMed ID: 9305677
    [Abstract] [Full Text] [Related]

  • 16. alpha-Interferon retreatment of patients with chronic hepatitis C.
    Rabinovitz M, Block G, Finkelstein SD.
    Am J Gastroenterol; 1996 Aug; 91(8):1523-6. PubMed ID: 8759654
    [Abstract] [Full Text] [Related]

  • 17. Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong.
    Yuen MF, Lai CL.
    Intervirology; 2006 Aug; 49(1-2):96-8. PubMed ID: 16166796
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.
    Mazzaro C, Carniello GS, Colle R, Doretto P, Mazzi G, Crovatto M, Santini GF, Tulissi P, Gregoretti M, Mazzoran L, Russo A, Silvestri F, Pozzato G.
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):343-50. PubMed ID: 9476189
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.